Fusion Pharmaceuticals Appoints Philina Lee, Ph.D., to Board of Directors

Rhea-AI Summary

Fusion Pharmaceuticals (Nasdaq: FUSN) announced the appointment of Dr. Philina Lee to its Board of Directors. Dr. Lee, with over 15 years of biopharmaceutical experience, was previously head of U.S. marketing for Algeta, known for the first alpha-emitting radiopharmaceutical. CEO John Valliant emphasized her experience in precision oncology and commercial launch strategies as vital during the company's growth. The board size increased from seven to eight members, enabling more robust strategic planning for Fusion's Targeted Alpha Therapies platform, which aims to advance cancer treatments.

Positive

• Dr. Philina Lee's extensive experience in precision oncology and radiopharmaceuticals can enhance Fusion's strategy.
• Her background in launching alpha therapy products will guide Fusion's growth and operational decisions.

Negative

• None.

HAMILTON, Ontario and BOSTON, Feb. 11, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Philina Lee, Ph.D., as a member of the Company's Board of Directors. Dr. Lee, who currently serves as senior vice president, head of portfolio strategy at Blueprint Medicines Corporation, brings to the board 15 years of experience in the biopharmaceutical industry. She previously was head of U.S. marketing for Algeta, developer of the first marketed alpha-emitting radiopharmaceutical.

"Philina's depth of both precision oncology and radiopharmaceutical industry experience will be valuable to us as we continue to progress our Targeted Alpha Therapies (TAT) platform and grow our pipeline of clinical candidates," said Fusion Chief Executive Officer John Valliant, Ph.D. "Additionally, her leadership and understanding relating to the commercial launch of an alpha therapy product will provide Fusion with important organizational, strategic and operational guidance during this growth period." 

Dr. Lee joined Blueprint Medicines in 2014 and has served in positions of increasing responsibility, including leading new product strategy, establishing the commercial organization, building infrastructure to enable patient access, and leading multiple new product launches. In her current role she is responsible for providing strategic and operational leadership across the portfolio, leading the portfolio management team as well as the program leadership and program management functions.

Prior to joining Blueprint Medicines, Dr. Lee served as head of U.S. marketing at Algeta ASA, where she was the second hire in the U.S. In this role, she contributed to building the fully-integrated organization that successfully launched Xofigo® (radium-223 dichloride), a first-in-class alpha-emitting radiopharmaceutical. Algeta was acquired by Bayer AG in 2014.

Dr. Lee holds a Ph.D. from the Massachusetts Institute of Technology and a B.S. from the University of Alberta.

"I see significant potential to use Fusion's Targeted Alpha Therapies (TAT) platform to build a strong portfolio of precision medicines," said Dr. Lee. "I'm excited to join the board, as I share the Fusion team's passion for improving the lives of cancer patients. I look forward to contributing to Fusion's strategic planning and growth."

The number of seats on the Fusion Board of Directors was increased to eight from seven immediately prior to Dr. Lee's election.

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-philina-lee-phd-to-board-of-directors-301226902.html

SOURCE Fusion Pharmaceuticals Inc.

FAQ

Who is Dr. Philina Lee and what experience does she bring to Fusion Pharmaceuticals?

Dr. Philina Lee is a newly appointed board member of Fusion Pharmaceuticals, bringing over 15 years of biopharmaceutical experience, including a leadership role at Blueprint Medicines and head of U.S. marketing at Algeta.

What is the significance of Dr. Lee's appointment to the Fusion Pharmaceuticals board?

Dr. Lee's appointment is significant due to her expertise in precision oncology and radiopharmaceuticals, which is expected to enhance Fusion's strategic planning and guidance during its growth phase.

How many members are now on the Fusion Pharmaceuticals Board of Directors?

The Fusion Pharmaceuticals Board of Directors has increased to eight members following Dr. Lee's appointment.

What is the Targeted Alpha Therapies platform at Fusion Pharmaceuticals?

The Targeted Alpha Therapies platform at Fusion Pharmaceuticals focuses on developing next-generation radiopharmaceuticals aimed at precision medicine for cancer treatment.